Please assess the completion status of the following clinical trial:

Trial Title: Artesunate Plus Sulfadoxine-pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant female, older than 18 years, \> 35kg.~* Gestational age \> 16 weeks (fundal height \> 16cm) and below 36 weeks gestation.~* Diagnoses of uncomplicated acute P. falciparum malaria parasitaemia of up to 250 000 asexual parasites/ul blood with axillary temperature of greater than or equal to 37.5°C or history of fever (defined as fever within the previous 24 hours).~* Documented written informed consent.~* Lives close enough to the study site for reliable follow up and is willing to attend ANC and follow-up visits regularly.~* Is willing to stop taking folate for 7 days if applicable.~Exclusion Criteria:~* Has received anti-malarial treatment in the past 7 days.~* Severely ill (based on WHO Criteria for severe malaria ) or if patient is considered, in the opinion of the investigator or designee, to have moderately severe malaria (e.g. prostrate, repeated vomiting, dehydrated) or other danger signs (Appendix 2).~* Known hepatic or renal impairment~* Has received chloramphenicol or tetracyclines (including doxycycline) in the past 7 days or is likely to require these during the study period.~* History of G6PD deficiency.~* Has a history of allergy to any of the study drugs (including other sulphonamides e.g. cotrimoxazole, or other artemisinin derivatives e.g. co-artemether).~* Serious underlying disease that in the opinion of the clinic team and/or Principal Investigator would make the patient unsuitable for the study in terms of their safety or study analysis.~* Imminent delivery expected.~* Prior inclusion in this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artesunate plus sulphadoxine-pyrimethamine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).